|
|
Inaugural Session:1 - Welcome Address & Moderated by Mr Rajesh Jain, Chairman, CII National Committee on Biotechnology, Joint Managing Director, Panacea Biotec Ltd.
|
|
|
Inaugural Session:2 - Address by Mr Nata Menabde, WHO Representative Designate to India
|
|
|
Inaugural Session:3 - Address by Mr Satish Reddy, Chairman, CII National Committee on Drugs & Pharmaceuticals, MD & COO, Dr. Reddy’s Laboratories Ltd.
|
|
|
Inaugural Session:4 - Address by Mr Y K Gupta, Head- Pharmacology, All India Institute of Medical Sciences
|
|
|
Inaugural Session:5 - Address by Mr Steven T Smith, Health Attaché, Embassy of USA, New Delhi
|
|
|
Inaugural Session:6 - Release of Compendiums
|
|
|
Inaugural Session:7 - Concluding Remarks by the Moderator Mr Rajesh Jain, Chairman, CII National Committee on Biotechnology, Joint Managing Director, Panacea Biotec Ltd & close of Session
|
|
|
Session 1:1 - Moderator by Mr H K Mittal, Secretary, Technology Development Board, Ministry of Science and Technology
|
|
|
Session 1:2 - Mr V K Vinayak, Chief Scientific Officer, Panacea Biotec Ltd.
|
|
|
Session 1:3 - Mr Bakulesh M Khamar, Executive Director-Research, Cadila Pharmaceuticals Ltd.
|
|
|
Session 1:4 - Mr Sundeep Kumar, Head-Corporate Affairs, Novartis India Ltd.
|
|
|
Session 1:5 - Mr Arunabha Pradhan, Chief, Business Operations & Development, National Research Development Corporation
|
|
|
Session 1:6 - Mr Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
|
|
|
Session 2:1 - Moderator Mr Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
|
|
|
Session 2:2 - Mr Rajinder K Jalali, Vice President Medical Affairs & Clinical Research and Head – Global Pharmacovigilance, Ranbaxy Laboratories Ltd.
|
|
|
Session 2:3 - Mr Tom Woods, President, Woods International, LLC
|
|
|
Session 2:4 - Mr Tobby Simon, President, The Synergia Foundation - Knowledge Beyond Borders
|
|
|
Session 2:5 - Mr Premnath Shenoy, Director- Regulatory Affairs AstraZeneca Pharma India Ltd.
|
|
|
Session 2:6 - Discussion of Session II : Safe Medicine-Requirements & Availability
|
|
|
Session 3:1 - Moderator - Mr Harsh Manglik, Senior Advisor, Accenture
|
|
|
Session 3:2 - Mr. Raman Govindarajan, Head India R&D, Sanofi Aventis Ltd.
|
|
|
Session 3:3 - Mr. Balu Chopade, Director, Institute of Bioengineering & Bioinformatics, University of Pune
|
|
|
Session 3:4 - Mrs. Malathi Lakshmi Kumaran, Consultant, Lakshmi Kumaran & Sridharan
|
|
|
Session 3:5 - Mrs. S N Khan, Scientist- F, Department of Science & Technology, Ministry of Science and Technology
|
|
|
Session 3:6 - Question & Answer
|
|
|
Session 4:1 - Moderator, Mr. R K Das, General Manager, SIDBI
|
|
|
Session 4:2 - Mr. Michael Ryan, Georgetown University Business School, Washington, DC
|
|
|
Session 4:3 - Mr. Prashanta Banerjee, Industrial Engineering, Bioengineering, Computer Science and Ophthalmology & Visual Science, University of Illinois
|
|
|
Session 4:4 - Mr. Jay Kesan, Professor and Director of IP Law, University of Illinois at Urbana
|
|
|
Session 4:5 - Mr. Shailendra Tandon, Cheif Finacial Officer, Asian Healthcare fund
|
|
|
Session 4:6 - Mr. Vishal Gandhi, VP & Head Life Science Banking, Yes Bank Ltd.
|
|
|
Session 5:1 - Moderator, Mr. Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
|
|
|
Session 5:2 - Mr. Janet McNicholas, K & L Gates, LLP, Chicago & Palo Alto
|
|
|
Session 5:3 - Ms. Rachal Winger, K & L Gates, LLP, Seattle
|
|
|
Session 5:4 - Ms. Malathi Lakshmi Kumaran, Consultant, Lakshmi Kumaran & Sridharan
|
|
|
Session 5:5 - Mr. Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
|
|
|
Session 5:6 - Mr. Pravin Anand, Managing Partner, Anand And Anand
|
|
|
Session 6:1 - Session Moderator, Mr V M Katoch, Director General, ICMR & Secretary, Health Services, Ministry of Health and Family Welfare
|
|
|
Session 6:2 - Mr Raman Govindarajan, Head India R&D, Sanofi Aventis Ltd.
|
|
|
Session 6:3 - Mr T K Chakraborty, Director, Central Drug Research Institute
|
|
|
Session 6:4 - Mr Arunabha Pradhan, Chief, Business Operations & Development, National Research Development Corporation
|
|
|
Session 6:5 - Ms. Monika Verma, Director, Dept of Pharmaceuticals, Ministry of Chemicals and Fertilizers
|
|
|
Session 6:6 - Dr. Syeda Saiyidain Hameed, Member Planning
|
|
|
Session 6:7 - Mr. R Ram A Vishwakarma, Director, Indian Institute of Integrative Medicine (IIIM)
|
|
|
Session 6:8 - Ms. Soumya Swaminathan, Director in-charge, National institute for research in tuberculosis
|
|
|
Session 6:9 - Ms. Jyoti Yadav, Head- PME, Institute of Genomics & Integrative Biology (IGIB)
|
|
|
Session 6:9a - Ms. Brinda K Varma, Innovation Centre, Indian Institute of Science
|
|
|
Session 6:9b - Mr. Ketan Divang,Mr. Ketan Divang addressing at the Session VI- CTO/CSO Conference
|
|
|
Session 6:9c - Concluding Remarks at the Session VI- CTO/CSO Conference
|